LANTUS® Plus Orals: Glycemic Control Compared to Premix Insulin

Adding LANTUS® to oral diabetes medications (OADs) produced predictable glycemic control⁸.

For type 2 diabetes patients with characteristics similar to the patients studied⁹:

• Mean duration of diabetes: 9.9 (± 6.8) years
• Mean BMI: 29.5 (± 3.6)
• A1C
  • Mean: 8.84% (± 0.92%)
  • Entry criteria: 7.5%-10.5%

A 24-week, multicenter trial of patients with type 2 diabetes (N=364) compared the efficacy and safety of adding once-daily LANTUS® basal insulin to prestudy OADs (sulfonylurea and metformin) vs switching to twice-daily premixed insulin (human insulin 70/30) in patients insufficiently controlled on OADs. Baseline A1C: premix = 8.83 (± 0.87).

From Janka et al.⁸

LANTUS®, a basal insulin, + oral diabetes medications (OADs) effectively reduced A1C⁸

• In two additional studies with LANTUS® and OADs, patients poorly controlled with a premix regimen experienced mean A1C reductions of 1.1%.
  • In one study, mean FBG reductions of 57-62 mg/dL were demonstrated. Of the 72% of subjects who were insulin pretreated at inclusion, 23.2% used premix insulin¹⁰
  • In the second study, mean FBG reductions of 54 mg/dL were demonstrated¹¹

Once-daily LANTUS® + OADs produced a low rate of hypoglycemia per patient⁹